Shenzhen AlphaMol Technology Co., Ltd. (“AlphaMol”) recently has announced the completion of the Series A round of financing.
AlphaMol is a new drug research and development platform in the GPCR (G protein-coupled receptor) field, focusing on the use of biocomputing, artificial intelligence, and original biotechnology for innovative drug research and development, especially in the GPCR signaling pathway related. GPCR are the largest and most diverse group of membrane receptors in eukaryotes, which can have significant impacts on various aspects of human physiological metabolism.
According to AlphaMol, it has multiple biotechnologies, including biochips for GPCR testing, biochips for cell electrophysiology testing, and biochips for tracking single molecule cells. The company has created an accurate GPCR new drug research and development platform that can efficiently screen, design, and optimize drug molecules, and quickly obtain clinical candidate molecules. Breakthrough progress has been made in the research and development of new drugs in multiple disease fields such as anticancer, metabolism, and pain relief.
According to IMARC Group, the global GPCRs market was worth USD 3.2 billion in 2022 and is expected to reach USD 4.7 billion by 2028, with a compound annual growth rate of 6.52%. This growth is driven by a rising number of cancer cases, extensive research and development activities, and various automation improvements.
In addition to AlphaMol, many companies are competing in the GPCRs market, such as HD Biosciences (辉源生物), Sanyou Bio (三优生物), Structure Therapeutics (硕迪生物), Yuyao Biotech (宇耀生物) in China, PerkinElmer, Enzo Biochem, Merck, HD Biosciences, Molecular Devices in the United States, Abcam in the United Kingdom, Confo Therapeutics in Belgium, and Domain Therapeutics in France.
Dr. Shuguang Yuan, founder and CEO of AlphaMol, stated: “AlphaMol has always adhered to independent innovation, focusing on its advantages in GPCR computing and biology, and adhering to differentiated and truly clinical research and development. In the future, AlphaMol will continue to take the clinical needs of patients as its mission, and with the support of new and old investors, continuously create new drug molecules faster and better to serve society.”
This round of financing for AlphaMol was exclusively invested by Shanghai Healthcare Capital (上海生物医药基金), with follow-on investments from Huaqian Capital (华仟资本) and Xinhenglida Capital (新恒利达资本). This round of funds will mainly be used for the research and development of innovative drugs, the development of GPCR protein fields, and the application in AI computing and biology.